CClinicalTrials.gg
Status unknownNCT00022568Updated Dec 18, 2013

Vaccine Therapy in Treating Patients With Metastatic Melanoma

A Phase 1 interventional study of recombinant vaccinia-TRICOM vaccine in Melanoma (Skin), sponsored by Herbert Irving Comprehensive Cancer Center. Status unknown at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-18.

Sponsored by Herbert Irving Comprehensive Cancer Center · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2003), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Phase 1
Study type
Interventional
Ages
18 Years and older
Sex
All
01

Study summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.

PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic melanoma.

Read the detailed description

OBJECTIVES:

  • Determine the maximum tolerated dose of recombinant vaccinia-TRICOM vaccine in patients with metastatic melanoma.
  • Determine the clinical toxic effects of this vaccine in these patients.
  • Determine the safety of this vaccine in these patients.
  • Determine the clinical response of these patients to this vaccine.
  • Determine evidence of host anti-melanoma immune reactivity in these patients after treatment with this vaccine.

OUTLINE: This is a dose-escalation study.

Patients receive recombinant vaccinia-TRICOM vaccine once every 4 weeks for a total of 3 vaccinations. Patients with stable or responding disease may receive an additional course of vaccinations.

Cohorts of 3-6 patients receive escalating doses of recombinant vaccinia-TRICOM vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.

Quality of life is assessed at baseline, at each vaccine administration, and at study completion.

Patients are followed at 3 months.

PROJECTED ACCRUAL: A total of 12-18 patients will be accrued for this study within 6-12 months.

02

Conditions studied

  • Melanoma (Skin)

Browse trials for

Keywords

  • stage IV melanoma
  • recurrent melanoma
03

In context

Melanoma

3,006 studies on the registry are indexed under Melanoma; 520 are open to participants now.

Browse Melanoma studies →

Lead sponsor

Herbert Irving Comprehensive Cancer Center is the lead sponsor of 32 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed metastatic non-resectable cutaneous, subcutaneous, or lymph node malignant melanoma
  • Lesion(s) must be accessible to percutaneous injection
  • Measurable lesion(s)

    • At least 1.0 cm
  • Previously treated brain metastases with no evidence of disease or edema on MRI or CT scan allowed

    • At least 6 weeks since prior definitive therapy (surgery or radiotherapy)
  • No untreated or edematous metastatic brain lesions or leptomeningeal disease
  • No ascites or pleural effusions

PATIENT CHARACTERISTICS:

Age:

  • Over 18

Performance status:

  • ECOG 0-1

Life expectancy:

  • More than 3 months

Hematopoietic:

  • WBC at least 3,000/mm3
  • Platelet count at least 100,000/mm3
  • Absolute granulocyte count at least 3,000/mm3
  • Hemoglobin at least 10 g/dL

Hepatic:

  • Direct bilirubin no greater than 1.5 mg/dL
  • Transaminases no greater than 2 times upper limit of normal (ULN)
  • Alkaline phosphatase no greater than 2 times ULN
  • No severe coagulation disorder with PT/PTT greater than 2 times normal (without anticoagulation medications)
  • No hepatic insufficiency
  • No alcoholic cirrhosis

Renal:

  • Creatinine no greater than 2.0 mg/dL OR
  • Creatinine clearance at least 60 mL/min
  • No renal insufficiency

Cardiovascular:

  • No congestive heart failure
  • No serious cardiac arrhythmias
  • No evidence of recent prior myocardial infarction on EKG
  • No clinical coronary artery disease

Pulmonary:

  • No chronic obstructive pulmonary disease

Immunologic:

  • No prior eczema
  • HIV negative
  • No immunocompromising conditions, (e.g., active autoimmune disease, leukemia, lymphoma, skin diseases, or open wounds)
  • No clinical or laboratory evidence of an underlying immunosuppressive disorder
  • No active or chronic infections
  • No significant allergy or hypersensitivity to eggs

Other:

  • No active seizure disorders
  • No other malignancy within the past 2 years except stage I cervical cancer or basal cell skin cancer, provided the tumor has been successfully treated and patient is currently disease free
  • No evidence of bone marrow toxicity
  • No other concurrent medical illness that would preclude study
  • No other contraindications to vaccinia virus administration
  • No encephalitis
  • Must be able to avoid close contact with children under 3 years of age; pregnant women; individuals with prior or active eczema or other open skin conditions; or immunosuppressed individuals for 7-10 days after each vaccination
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Prior vaccinia immunization required (e.g., smallpox vaccination)
  • More than 8 weeks since prior immunotherapy and recovered
  • No prior therapy with live vaccinia virus vector

Chemotherapy:

  • More than 4 weeks since prior chemotherapy and recovered

Endocrine therapy:

  • At least 4 weeks since prior systemic corticosteroids
  • No concurrent systemic corticosteroids
  • No concurrent steroids

Radiotherapy:

  • See Disease Characteristics
  • More than 2 weeks since prior radiotherapy and recovered

Surgery:

  • See Disease Characteristics
  • More than 4 weeks since prior surgery for primary tumor or metastatic lesions and recovered

Other:

  • No concurrent immunosuppressive drugs
05

Study design

Phase
Phase 1
Primary purpose
Treatment

Interventions

  • Biologicalrecombinant vaccinia-TRICOM vaccine
06

Study locations

1 site
  • Herbert Irving Comprehensive Cancer Center at Columbia University
    New York, New York 10032, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00022568
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Collaborators
National Cancer Institute (NCI)
First posted
Jan 27, 2003
Start date
Aug 2001
Last update
Dec 18, 2013

Study contacts

Howard L. Kaufman, MD
study chair · Herbert Irving Comprehensive Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2003. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion